No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19

References

• Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020;4(4):66–6. doi:10.15698/cst2020.04.216.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368:m1198. doi:10.1136/bmj.m1198.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. doi:10.1016/j.jinf.2020.04.021.
   PubMed Web of Science ®Google Scholar
• Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020. doi:10.1056/NEJMcp2009575.
   PubMed Web of Science ®Google Scholar
• Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544. doi:10.1038/s41564-020-0695-z.
   PubMed Web of Science ®Google Scholar
• Melenotte C, Silvin A, Goubet AG, Lahmar I, Dubuisson A, Zumla A, Raoult D, Merad M, Gachot B, Hénon C, et al. Immune responses during COVID-19 infection. Oncoimmunology. 2020;9(1):1807836. doi:10.1080/2162402X.2020.1807836.
   PubMed Web of Science ®Google Scholar
• Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, Storgaard M, Al Khalili S, Simonsen L, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–e44. doi:10.1016/S1473-3099(20)30484-9.
   PubMed Web of Science ®Google Scholar
• Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384. doi:10.1038/ni.1863.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Le Naour J, Kroemer G. The ambiguous role of FPR1 in immunity and inflammation. Oncoimmunology. 2020;9(1):1760061. doi:10.1080/2162402X.2020.1760061.
   PubMed Web of Science ®Google Scholar
• Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Nuevo A, Zorzano A. The sensing of mitochondrial DAMPs by non-immune cells. Cell Stress. 2019;3(6):195–207. doi:10.15698/cst2019.06.190.
   PubMedGoogle Scholar
• Vacchelli E, Enot DP, Pietrocola F, Zitvogel L, Kroemer G. Impact of pattern recognition receptors on the prognosis of breast cancer patients undergoing adjuvant chemotherapy. Cancer Res. 2016;76(11):3122–3126. doi:10.1158/0008-5472.CAN-16-0294.
   PubMed Web of Science ®Google Scholar
• Venereau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol. 2015;6:422. doi:10.3389/fimmu.2015.00422.
   PubMed Web of Science ®Google Scholar
• Banoth B, Cassel SL. Mitochondria in innate immune signaling. Transl Res. 2018;202:52–68. doi:10.1016/j.trsl.2018.07.014.
   PubMed Web of Science ®Google Scholar
• Kroemer G. Mitochondrial implication in apoptosis. Towards an endosymbiont hypothesis of apoptosis evolution. Cell Death Differ. 1997;4(6):443–456. doi:10.1038/sj.cdd.4400266.
   PubMed Web of Science ®Google Scholar
• Ernst S, Lange C, Wilbers A, Goebeler V, Gerke V, Rescher U. An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family. J Immunol. 2004;172(12):7669–7676. doi:10.4049/jimmunol.172.12.7669.
   PubMed Web of Science ®Google Scholar
• Foo SL, Yap G, Cui J, Lim LHK. Annexin-A1 – A blessing or a curse in cancer? Trends Mol Med. 2019;25(4):315–327. doi:10.1016/j.molmed.2019.02.004.
   PubMed Web of Science ®Google Scholar
• Perretti M. The annexin 1 receptor(s): is the plot unravelling? Trends Pharmacol Sci. 2003;24(11):574–579. doi:10.1016/j.tips.2003.09.010.
   PubMed Web of Science ®Google Scholar
• Scannell M, Flanagan MB, deStefani A, Wynne KJ, Cagney G, Godson C, Maderna P. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol. 2007;178(7):4595–4605. doi:10.4049/jimmunol.178.7.4595.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350(6263):972–978. doi:10.1126/science.aad0779.
   PubMed Web of Science ®Google Scholar
• Walther A, Riehemann K, Gerke V. A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell. 2000;5(5):831–840. doi:10.1016/S1097-2765(00)80323-8.
   PubMed Web of Science ®Google Scholar
• Dorward DA, Lucas CD, Chapman GB, Haslett C, Dhaliwal K, Rossi AG. The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation. Am J Pathol. 2015;185(5):1172–1184. doi:10.1016/j.ajpath.2015.01.020.
   PubMed Web of Science ®Google Scholar
• Liu M, Chen K, Yoshimura T, Liu Y, Gong W, Wang A, Gao J-L, Murphy PM, Wang JM. Formylpeptide receptors are critical for rapid neutrophil mobilization in host defense against Listeria monocytogenes. Sci Rep. 2012;2(1):786. doi:10.1038/srep00786.
   PubMedGoogle Scholar
• Zhang M, Gao J-L, Chen K, Yoshimura T, Liang W, Gong W, Li X, Huang J, McDermott DH, Murphy PM, et al. A critical role of formyl peptide receptors in host defense against Escherichia coli. J Immunol. 2020;204(9):2464–2473. doi:10.4049/jimmunol.1900430.
   PubMed Web of Science ®Google Scholar
• Osei-Owusu P, Charlton TM, Kim HK, Missiakas D, Schneewind O. FPR1 is the plague receptor on host immune cells. Nature. 2019;574(7776):57–62. doi:10.1038/s41586-019-1570-z.
   PubMed Web of Science ®Google Scholar
• Zhou QL, Teng F, Zhang YS, Sun Q, Cao YX, Meng GW. FPR1 gene silencing suppresses cardiomyocyte apoptosis and ventricular remodeling in rats with ischemia/reperfusion injury through the inhibition of MAPK signaling pathway. Exp Cell Res. 2018;370(2):506–518. doi:10.1016/j.yexcr.2018.07.016.
   PubMed Web of Science ®Google Scholar
• Lammers KM, Chieppa M, Liu L, Liu S, Omatsu T, Janka-Junttila M, Casolaro V, Reinecker H-C, Parent CA, Fasano A, et al. Gliadin induces neutrophil migration via engagement of the formyl peptide receptor, FPR1. PLoS One. 2015;10(9):e0138338. doi:10.1371/journal.pone.0138338.
   PubMed Web of Science ®Google Scholar
• Grommes J, Drechsler M, Soehnlein O. CCR5 and FPR1 mediate neutrophil recruitment in endotoxin-induced lung injury. J Innate Immun. 2014;6(1):111–116. doi:10.1159/000353229.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang T, Yuan ZC, Dai LQ, Zeng N, Wang H, Liu L, Wen FQ. Mitochondrial peptides cause proinflammatory responses in the alveolar epithelium via FPR-1, MAPKs, and AKT: a potential mechanism involved in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2018;315(5):L775–L86. doi:10.1152/ajplung.00466.2017.
   PubMed Web of Science ®Google Scholar
• Cardini S, Dalli J, Fineschi S, Perretti M, Lungarella G, Lucattelli M. Genetic Ablation of the Fpr1 gene confers protection from smoking-induced lung emphysema in mice. Am J Respir Cell Mol Biol. 2012;47(3):332–339. doi:10.1165/rcmb.2012-0036OC.
   PubMed Web of Science ®Google Scholar
• Stockley RA, Grant RA, Llewellyn-Jones CG, Hill SL, Burnett D. Neutrophil formyl-peptide receptors. Relationship to peptide-induced responses and emphysema. Am J Respir Crit Care Med. 1994;149(2):464–468. doi:10.1164/ajrccm.149.2.8306047.
   PubMed Web of Science ®Google Scholar
• Leslie J, Millar BJ, Del Carpio Pons A, Burgoyne RA, Frost JD, Barksby BS, Luli S, Scott J, Simpson AJ, Gauldie J, et al. FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis. JCI Insight. 2020;5(4). doi:10.1172/jci.insight.125937.
   PubMed Web of Science ®Google Scholar
• Baracco EE, Pietrocola F, Buque A, Bloy N, Senovilla L, Zitvogel L, Vacchelli E, Kroemer G. Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. Oncoimmunology. 2016;5(6):e1139275. doi:10.1080/2162402X.2016.1139275.
   PubMed Web of Science ®Google Scholar
• Sahagun-Ruiz A, Colla JS, Juhn J, Gao JL, Murphy PM, McDermott DH. Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. Genes Immun. 2001;2(6):335–342. doi:10.1038/sj.gene.6363787.
   PubMed Web of Science ®Google Scholar
• Le Naour J, Liu P, Zhao L, Adjemian S, Sztupinszki Z, Taieb J, Mulot C, Silvin A, Dutertre CA, Ginhoux F, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. Cancer Discov. pp.CD-20-0465. 2020. doi:10.1158/2159-8290.CD-20-0465
   PubMed Web of Science ®Google Scholar
• Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernández J, Prati D, Baselli G, Asselta R, et al. Genomewide Association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020;383:1522-1534. doi:10.1056/NEJMoa2020283.
   PubMed Web of Science ®Google Scholar
• Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L,Sharifi N, Erzurum S, Eng C, Cheng F. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020;18:216. doi:10.1186/s12916-020-01673-z.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 2010;128(1):119–128. doi:10.1016/j.pharmthera.2010.06.003.
   PubMed Web of Science ®Google Scholar
• Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol Rev. 2020;296(1):205–219. doi:10.1111/imr.12897.
   PubMed Web of Science ®Google Scholar
• Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol. 2017;18(1):76. doi:10.1186/s13059-017-1207-1.
   PubMedGoogle Scholar
• Sambaturu N, Mukherjee S, Lopez-Garcia M, Molina-Paris C, Menon GI, Chandra N. Role of genetic heterogeneity in determining the epidemiological severity of H1N1 influenza. PLoS Comput Biol. 2018;14(3):e1006069. doi:10.1371/journal.pcbi.1006069.
   PubMed Web of Science ®Google Scholar
• Skevaki C, Pararas M, Kostelidou K, Tsakris A, Routsias JG. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases. Clin Exp Immunol. 2015;180(2):165–177. doi:10.1111/cei.12578.
   PubMed Web of Science ®Google Scholar